New combo therapy targets Hard-to-Treat lymphoma
NCT ID NCT04827862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of an immunotherapy drug (pembrolizumab) and low-dose radiation for people with non-Hodgkin lymphoma that has come back or not responded to prior treatments. Six participants will receive the drug plus radiation to one or more tumor sites. The goal is to see if this approach can shrink tumors and control the disease, but participants will continue immunotherapy long-term unless side effects or progression occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abamson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States